Literature DB >> 3905335

Current management of Hodgkin's disease.

B C Behrens, R C Young, V T DeVita.   

Abstract

The prognosis of patients with Hodgkin's disease has dramatically improved over the past few decades. Treatment with currently standard radiotherapy or combination chemotherapy programmes will result in durable complete remissions and probable cure in most patients. However, these programmes are intensive, technically demanding, and associated with a risk of certain acute side effects and long term complications which vary in nature and severity according to the specific therapy employed. The outlook for the few patients who do not achieve complete remission with induction therapy, or for those who later relapse (especially after complete remissions induced by chemotherapy), is less optimistic. Current trials of innovative induction and salvage therapies may lead to improved treatment approaches for such patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3905335     DOI: 10.2165/00003495-198530040-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  77 in total

1.  Occurrence of non-Hodgkin's lymphoma after therapy for Hodgkin's disease.

Authors:  J G Krikorian; J S Burke; S A Rosenberg; H S Kaplan
Journal:  N Engl J Med       Date:  1979-03-01       Impact factor: 91.245

2.  Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease.

Authors:  A Santoro; V Bonfante; G Bonadonna
Journal:  Ann Intern Med       Date:  1982-02       Impact factor: 25.391

3.  A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy.

Authors:  P Carde; F R MacKintosh; S A Rosenberg
Journal:  J Clin Oncol       Date:  1983-02       Impact factor: 44.544

4.  Role of radiation therapy in the treatment of Hodgkin's disease.

Authors:  S Hellman; P Mauch
Journal:  Cancer Treat Rep       Date:  1982-04

5.  Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease.

Authors:  J Pedersen-Bjergaard; S O Larsen
Journal:  N Engl J Med       Date:  1982-10-14       Impact factor: 91.245

6.  Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy.

Authors:  R C Young; G P Canellos; B A Chabner; S M Hubbard; V T DeVita
Journal:  Cancer       Date:  1978-08       Impact factor: 6.860

7.  New multiple-agent chemotherapy (B-DOPA) for advanced Hodgkin's disease.

Authors:  J J Lokich; E Frei; N Jaffe; J Tullis
Journal:  Cancer       Date:  1976-08       Impact factor: 6.860

Review 8.  The control of chemotherapy-induced emesis.

Authors:  L J Seigel; D L Longo
Journal:  Ann Intern Med       Date:  1981-09       Impact factor: 25.391

9.  Female reproductive potential after treatment for Hodgkin's disease.

Authors:  S J Horning; R T Hoppe; H S Kaplan; S A Rosenberg
Journal:  N Engl J Med       Date:  1981-06-04       Impact factor: 91.245

10.  Long-term survival of patients with Hodgkin's disease. Treatment with cyclophosphamide, vinblastine, procarbazine, and prednisone.

Authors:  G E Gibbs; B A Peterson; B J Kennedy; G Vosika; C D Bloomfield
Journal:  Arch Intern Med       Date:  1981-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.